Forte Biosciences, Inc.
Description
Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.
About
CEO
Dr. Paul A. Wagner Ph.D.
Employees
11
Instrument type
Common Stock
Sector
Healthcare
Industry
Biotechnology
MIC code
XNCM
Address
3060 Pegasus Park Drive, Dallas, TX 75247, United States
×
![Enlarged Chart]()
Oscillators
No data available
Summary
No data available
Moving Averages
No data available
Earnings
| Date | Estimate EPS | Actual EPS | Difference | % Surprise |
|---|---|---|---|---|
| Nov 12, 2025 | — | — | — | — |
| Aug 12, 2025 | — | — | — | — |
| May 12, 2025 | — | — | — | — |
| Mar 17, 2025 | — | — | — | — |
Earnings estimate
|
Next Quarter
(Mar 2025)
|
Next Year
(Dec 2025)
|
|||
|---|---|---|---|---|
| Number of analysts | — | 1 | — | 3 |
| Average estimate | — | -0.76 | — | -3.56 |
| Low estimate | — | -0.76 | — | -4.03 |
| High estimate | — | -0.76 | — | -3.06 |
| Last year EPS | — | -4.00 | — | -11.91 |
[stock_revenue_estimate]
Growth estimates
Current qtr
-136.000%
Next qtr. (Mar 2025)
81.000%
Current year
52.350%
Next year (Dec 2025)
70.150%
Next 5 years (per annum)
—
Past 5 years (per annum)
—
Income statement
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total reported revenue | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating expense | |||||
| Research & development | 21.86M | 5.59M | 13.85M | 10.00M | — |
| Selling general and admin | 10.62M | 8.30M | 7.63M | 4.22M | — |
| Other operating expenses | — | — | — | — | — |
| Operating income | -32.49M | -13.90M | -21.49M | -14.23M | — |
| Non operating interest income | |||||
| Income | 1.12M | 162,000 | — | — | — |
| Expense | — | — | — | — | — |
| Other income expense | -114,000 | -145,000 | -222,000 | -32.26M | — |
| Pretax income | -31.48M | -13.88M | -21.71M | -46.49M | — |
| Tax provision | — | — | — | — | — |
| Net income | -31.48M | -13.88M | -21.71M | -46.49M | — |
| Basic EPS | -25.00 | -20.00 | -38.75 | -158.00 | -9.42 |
| Diluted EPS | -25.00 | -20.00 | -38.75 | -158.00 | -9.42 |
| Basic average shares | 1.26M | 695,341 | 558,712 | 294,357 | 431,984 |
| Diluted average shares | 1.26M | 695,341 | 558,712 | 294,357 | 431,984 |
| EBITDA | -32.48M | -13.90M | -21.45M | 17.89M | — |
| Net income from continuing op. | -31.48M | -13.88M | -21.71M | -46.49M | — |
| Minority interests | — | — | — | — | — |
| Preferred stock dividends | — | — | — | — | — |
Balance sheet
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 38.98M | 42.00M | 43.31M | 61.24M | 7.66M |
| Current assets | |||||
| Cash | 6.28M | 36.04M | — | — | 6.94M |
| Cash equivalents | 5.69M | 5.06M | — | — | — |
| Cash and cash equivalents | 11.96M | 41.10M | 42.04M | 58.77M | 6.94M |
| Other short term investments | 25.16M | — | — | — | — |
| Accounts receivable | — | — | — | — | — |
| Other receivables | — | — | — | — | — |
| Inventory | — | — | — | — | — |
| Prepaid assets | 1.04M | 341,000 | 387,000 | 1.06M | 514,250 |
| Restricted cash | — | — | — | — | — |
| Assets held for sale | — | — | — | — | — |
| Hedging assets | — | — | — | — | — |
| Other current assets | 165,000 | 70,000 | 89,000 | 76,000 | 53,172 |
| Non current assets | |||||
| Properties | 100,000 | — | — | — | — |
| Land and improvements | — | — | — | — | — |
| Machinery furniture equipment | 18,000 | — | — | — | — |
| Construction in progress | — | — | — | — | — |
| Leases | — | — | — | — | — |
| Accumulated depreciation | -9,000 | — | — | — | — |
| Goodwill | — | — | — | — | — |
| Investment properties | — | — | — | — | — |
| Financial assets | — | — | — | — | — |
| Intangible assets | — | — | — | — | — |
| Investments and advances | — | — | — | — | — |
| Other non current assets | 53,000 | 13,000 | 13,000 | 12,000 | — |
| Total liabilities | 3.67M | 3.18M | 1.76M | 2.26M | 12.43M |
| Current liabilities | |||||
| Accounts payable | 1.42M | 1.15M | 946,000 | 1.24M | 1.57M |
| Accrued expenses | 1.30M | 1.14M | 131,000 | 373,000 | 168,216 |
| Short term debt | — | — | — | — | — |
| Deferred revenue | — | — | — | — | — |
| Tax payable | — | — | — | — | — |
| Pensions | 947,000 | 890,000 | 681,000 | 646,000 | 175,000 |
| Other current liabilities | — | — | — | — | 27,528 |
| Non current liabilities | |||||
| Long term debt | — | — | — | — | — |
| Provision for risks and charges | — | — | — | — | — |
| Deferred liabilities | — | — | — | — | — |
| Derivative product liabilities | — | — | — | — | — |
| Other non current liabilities | — | — | — | — | — |
| Shareholders equity | |||||
| Common stock | 36,000 | 21,000 | 15,000 | 13,000 | 1,000 |
| Retained earnings | -118.52M | -87.04M | -73.17M | -51.46M | -4.97M |
| Other shareholders equity | 4,000 | — | — | — | — |
| Total shareholders equity | 35.31M | 38.82M | 41.55M | 58.98M | -4.77M |
| Additional paid in capital | 153.79M | 125.84M | 114.70M | 110.42M | 199,710 |
| Treasury stock | — | — | — | — | — |
| Minority interest | — | — | — | — | — |
Cash flow statement
| 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|
| Operating Activities | ||||
| Net Income | -31.48M | -13.88M | -21.71M | -46.49M |
| Depreciation | 9,000 | — | 36,000 | 54,000 |
| Deferred Taxes | — | — | — | — |
| Stock-Based Compensation | 3.28M | 4.02M | 4.21M | 956,000 |
| Other Non-Cash Items | -131,000 | — | — | 30.89M |
| Accounts Receivable | — | — | — | — |
| Accounts Payable | 271,000 | 207,000 | -294,000 | -369,000 |
| Other Assets & Liabilities | — | — | — | — |
| Operating Cash Flow | -28.04M | -9.66M | -17.75M | -14.96M |
| Investing Activities | ||||
| Capital Expenditures | -88,000 | — | — | — |
| Net Intangibles | — | — | — | — |
| Net Acquisitions | — | — | — | — |
| Purchase of Investments | -9.97M | — | — | — |
| Sale of Investments | 10.10M | — | — | — |
| Investing Cash Flow | 47,000 | — | — | 3.58M |
| Financing Activities | ||||
| Long-Term Debt Issuance | — | — | — | — |
| Long-Term Debt Payments | — | — | — | — |
| Other Financing Charges | -60,000 | — | -106,000 | -289,000 |
| Financing Cash Flow | 24.67M | 7.23M | -106,000 | 66.41M |
| Other Cash Details | ||||
| End Cash Position | 37.13M | 41.10M | 42.04M | 58.77M |
| Income Tax Paid | — | — | — | — |
| Interest Paid | — | — | — | — |
| Free Cash Flow | -28.79M | -8.19M | -16.68M | -18.42M |
Error: Invalid format in Holders JSON file.
Article
Forte Biosciences, Inc. to Present at Upcoming Investor Meetings
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced it will be presenting at two upcoming investor meetings. Forte's CEO, Paul Wagner, PhD will be presenting at the Guggenheim SMID Cap Biotech Conference at 1:30 PM ET on February 6th hosted at the Lotte New York Palace in New York, NY. Additionally, on March 3rd at 10:30 AM ET, Dr. Wagner will be pr.
Feb 3, 2025
Article
Forte Biosciences (FBRX) Is a Great Choice for 'Trend' Investors, Here's Why
Forte Biosciences (FBRX) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Jan 3, 2025
Article
Here's Why Momentum in Forte Biosciences (FBRX) Should Keep going
Forte Biosciences (FBRX) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Nov 28, 2024
